The global demand for herpes labialis treatment t is likely to register a CAGR of 4.7% between 2023 and 2033. FMI estimates that the global herpes labialis treatment market size could reach USD 1.79 billion by 2033, up from USD 1.13 billion in 2023. The high prevalence of herpes labialis simplex virus infections, especially oral herpes, is responsible for the expansion.
Herpes labialis, commonly termed oral herpes, is a mouth infection that results in the development of minute and uncomfortable blisters on the lips, gums, or neck. The herpes simplex virus, which is common and highly infectious and infects plenty of people in North America by the age of 20, is the source of these blisters. The infection is frequently brought on by Herpes Simplex Virus type 1 (HSV-1), although it can also be brought on by Herpes Simplex Virus type 2 (HSV-2).
Since herpes labialis infections are becoming more common globally, the herpes labialis treatment market has seen a surge in growth lately. The HSV-1 virus, which is the main cause of herpes labialis, is suspected of impacting 3.7 billion individuals under the age of 50. Based on a report from the World Health Organization in 2020.
Herpes labialis should always be diagnosed and treated as soon as possible to control the symptoms and stop the infection from spreading. More people are seeking immediate medical attention for herpes labialis. As a result of increased awareness of the significance of early diagnosis and treatment, leading to market expansion.
Herpes labialis is commonly treated with topical antiviral creams like acyclovir, penciclovir, and docosanol. Given their ease of use and comfort, these creams offer targeted therapy and are appreciated by patients. Topical antiviral creams are increasingly being used as the first line of therapy for herpes labialis, and this trend is anticipated to continue boosting the sales of these products.
Herpes labialis symptoms are also increasingly managed using over-the-counter (OTC) medicines such as lotions, ointments, and lip balms. These are well-liked by customers since they are easily available and can be purchased without a prescription. The demand for these products is anticipated to be driven by the tendency of self-medication and the increased availability of OTC medications in various retail channels.
Herpes labialis is also being treated with combination therapy, which includes antiviral drugs with topical creams or other treatment modalities, such as corticosteroids. There is potential for the development of groundbreaking combination treatments that could lead to better results in terms of symptom alleviation, a decrease in the frequency of outbreaks, and faster healing.
To provide affordable pharmaceuticals for the treatment of viral infections, several manufacturers are emphasizing the approval and introduction of generic treatments in developing countries. Hence, the increasing advancements in the prevention of herpes labialis infection are likely to present producers of herpes labialis medications with promising opportunities. For instance, Perrigo stated in February 2019 that a generic version of Bausch Health's Zovirax (acyclovir) cream has received FDA clearance and an AB rating.
| Attributes | Details |
|---|---|
| Herpes Labialis Treatment Market Value (2023) | USD 1.13 billion |
| Herpes Labialis Treatment Market Expected Value (2033) | USD 1.79 billion |
| Herpes Labialis Treatment Market Projected CAGR (2023 to 2033) | 4.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The herpes labialis treatment market expanded at a CAGR of 4.2% between 2018 and 2022.
A few of the primary drivers behind the market growth:
Depending on the individual, the frequency and intensity of herpes labialis outbreaks could vary. Around 20–40% of people with recurrent herpes labialis could suffer outbreaks at least once each year, based on certain research. Whereas others could experience less frequent recurrences. The United States Food and Drug Administration announced the updated recommendations for the development of antiviral medications, especially for the treatment of recurrent herpes labialis in November 2017. These recommendations were developed to aid in the investigation of safety testing, which is crucial for the approval of any antiviral medication.
FMI expects the herpes labialis treatment market may expand at a CAGR of 4.7% during the forecast period.
The dominance of North America over other regions of the global market is anticipated to increase with the presence of numerous notable companies in the region. In 2022, the United States accounted for around 92% share of the North America herpes labialis treatment market. This can be ascribed to increased use of premium herpes medications, rising healthcare expenditure, an increase in the introduction of generic medications, and supportive reimbursement policies.
By establishing criteria for the safety and effectiveness of therapies, the United States Food and Drug Administration plays a critical role in regulating the herpes labialis treatment industry. In recent years, the United States FDA has authorized many novel medications and herpes labialis therapy alternatives. For instance, the FDA authorized the topical cream Xerese (acyclovir and hydrocortisone) in 2020 for the treatment of recurrent herpes labialis in immunocompetent individuals. With receiving this clearance, patients with herpes labialis in the United States now have more treatment alternatives.
The United States herpes labialis treatment market is also being driven by variables including rising disease prevalence, an aging and immunocompromised population, and an increase in serological testing for herpes infection. For instance, the CDC estimates that in the United States, 11.9% of individuals between the ages of 11 and 49 are infected. The commencement of an observational clinical study for recurrent HSV-2 infection with 200 patients for the company's product RVx-001-PSS was announced by Rational Vaccines Inc. in August 2022.
Market participants in the United States have joined forces and made acquisitions to diversify their product portfolios and increase their market share. For instance, TESARO Inc., a biopharmaceutical business with a pipeline of experimental cancer therapies, including a possible therapy for herpes labialis, was obtained by GlaxoSmithKline (GSK) in 2020. These partnerships and purchases may help the market generate new and better therapeutic solutions.
Germany held about 22% share of the Western Europe herpes labialis treatment market in the year 2022. The Germany herpes labialis treatment market is experiencing growth since there is a growing patient population with HSV infections and improved facilities for healthcare. According to the Robert Koch Institute, the estimated prevalence of HSV-1 infection, which is a common cause of herpes labialis, in Germany is around 60-90% of the population.
The utilization and approval of drugs for herpes labialis are governed by Germany regulatory agencies. Such as the Federal Institute for Drugs and Medical Devices and the Paul-Ehrlich Institute. These guidelines make sure that the treatment alternatives on the market are both safe and efficient, as well as meeting the required levels of quality, which in turn increases public confidence in the market.
Recent developments in the production of antiviral drugs and topical creams for the treatment of herpes labialis have occurred in Germany. Also, there has been an increase in demand for herbal and natural treatments in Germany for the treatment of herpes labialis. Players in the market are developing products with natural components renowned for their antiviral characteristics, such as tea tree oil and lemon balm.
China accounted for 44.3% share 2022 of the Asia Pacific herpes labialis treatment market. Herpes labialis is becoming more common in China, which has increased the demand for effective treatment alternatives and fueled market expansion. Given government investments in enhancing healthcare infrastructure and facilities, China has seen a growth in healthcare expenditure. The market has grown as a consequence of easier access to healthcare services, especially those for herpes labialis diagnosis and treatment.
China herpes labialis treatment market is expected to expand at a CAGR of 6.1% from 2023 to 2033. Herpes labialis is one of several illnesses that are commonly treated in China with Traditional Chinese medicine (TCM). Herbal medications, acupuncture, and other TCM-based treatments have grown increasingly well-liked in China because many believe they work better and have fewer adverse effects than conventional therapies. This has increased demand in China for TCM-based herpes labialis therapies.
The herpes labialis treatment industry in China is actively occupied by numerous both local and international pharmaceutical companies, fostering competition and innovation. For instance, the National Medical Products Administration (NMPA) granted permission to Livzon Pharmaceutical Group Inc. In 2019 for their acyclovir cream, which is used to treat herpes labialis. Livzon is a well-known pharmaceutical business in China.
Principal Consultant
The commonly prescribed medication for treating cold sores is acyclovir. Thus, sales of acyclovir are projected to expand at a CAGR of 5.1% over the forecast period. Acyclovir functions by preventing the HSV from replicating, lessening the severity and length of outbreaks, and easing symptoms like pain and suffering related to cold sores. Patients can easily and conveniently get acyclovir since it comes in a variety of forms, including topical creams, ointments, and oral pills.
Healthcare professionals and individuals are becoming more knowledgeable about herpes labialis. As a result, the advantages of acyclovir in treating the illness are becoming more widely acknowledged. Acyclovir is now being given for herpes labialis more frequently as a result, which has raised the demand for the medication in the market.
The hospitals segment held a 35.4% market share in terms of distribution in 2022, showing strong sales of herpes labialis treatment medications through hospital pharmacies. The expansion could additionally be attributed to the availability of comprehensive treatment and expert medical personnel in hospitals. With expertise in diagnosis and treatment, hospitals offer a wide range of options including antiviral medications, pain management, and supportive therapies.
Hospitals keep up with the recent developments in the industry because they have cutting-edge diagnostic equipment and facilities. Given their reliability, hospitals are frequently preferred by patients for herpes labialis therapy. The inclusion of hospitals in insurance coverage plans and their referral network from other healthcare providers also help to increase their market share.
| Company | GlaxoSmithKline |
|---|---|
| Development | Shingrix, a recombinant herpes zoster vaccine produced by GlaxoSmithKline, received FDA clearance in the United States in July 2021. When an adult over the age of 18 is in danger of getting herpes zoster owing to any known immunosuppressive factors, this can be utilized as a preventative measure. |
| Strategy | GSK's strategy for Shingrix includes identifying the target market of immunosuppressed adults at risk for shingles and comprehending their requirements and preferences. It also focuses on pricing the vaccine competitively and putting in place marketing initiatives to increase awareness and encourage adoption. |
| Company | Amneal Pharmaceuticals, LLC |
|---|---|
| Development | In November 2020, for the prevention of recurrent herpes labialis (cold sores) in immunocompetent individuals who are 12 years of age and older, Amneal Pharmaceuticals, LLC officially declared that the FDA has accepted its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%, the substitute for Zovirax. |
| Strategy | Amneal Pharmaceuticals, LLC aims to gain ground in the market for preventing recurrent herpes labialis. The approach focuses on offering a cost-effective substitute for the branded medicine while leveraging the existing market need for herpes labialis treatments, with a target audience of immunocompetent adults aged 12 and older. |
| Company | Bayer AG |
|---|---|
| Development | Bayer AG started the investigation for the treatment of herpes labialis in patients with a healthy immune system using the sitavig (acyclovir) buccal tablet. It also reported that it is undertaking Phase 3 clinical investigations in June 2022. By October 2023, the study is anticipated to be finished. |
| Strategy | With a strategic focus on completing its clinical studies and securing regulatory permission for commercialization, Bayer AG appears to be actively encouraging the development of Sitavig as a potential therapy for this disease. |
| Company | GC Biopharma Inc. |
|---|---|
| Development | GC Biopharma Inc. unveiled Pojinen cream, an OTC medication, in January 2022 as a combined treatment for recurrent herpes labialis. The cream includes 10mg/g of hydrocortisone, which has anti-inflammatory qualities, and 50mg/g of acyclovir, which stops the herpes virus from multiplying. The combination of these substances aims to shorten the typical treatment period. |
| Strategy | The goal of GC Biopharma Inc. is to reduce the duration of medication for recurrent herpes labialis by offering a combination treatment approach that tackles both viral replication and inflammation. Moreover, it distinguishes itself by a dual-action strategy, a focus on effectiveness, and comprehensive customer education. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Expanding in the herpes labialis treatment market can be challenging given the competitive landscape and regulatory requirements. Nonetheless, there are several strategies that market players can consider to increase their presence in the market:
The market is valued at USD 1.1 billion in 2023.
Novartis AG, and Teva Pharmaceuticals Industries Ltd. are key market players.
The market’s CAGR from 2023 to 2033 will be 4.7%.
Rising use of systemic antiviral drugs for severe and recurrent cases.
Acyclovir segment is likely to remain preferred through 2033.
1. Executive Summary | Herpes Labialis Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Acyclovir 5.2. Valacyclovir 5.3. Penciclovir 5.4. Famciclovir 5.5. Docosanol 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Topical 6.3. Combination 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Novartis AG 18.2. Valeant Pharmaceuticals International Inc. 18.3. Teva Pharmaceuticals Industries Ltd. 18.4. Sun Pharmaceuticals 18.5. Abbott Laboratories 18.6. Mylan N.V. 18.7. Pfizer Inc. 18.8. GlaxoSmithKline PLC 18.9. Dr. Reddy’s Laboratories 18.10. Merck & Co., Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Herpes Labialis Treatment Market
